| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/05/2024 | 08:30 | GlobeNewswire Inc. | Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor | EU:IVA | Inventiva |
| 13/05/2024 | 08:30 | GlobeNewswire Inc. | Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité | EU:IVA | Inventiva |
| 03/04/2024 | 22:00 | GlobeNewswire Inc. | Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | EU:IVA | Inventiva |
| 03/04/2024 | 22:00 | GlobeNewswire Inc. | Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») | EU:IVA | Inventiva |
| 28/03/2024 | 08:00 | GlobeNewswire Inc. | Inventiva announces the nomination of Andre Turenne as Director | EU:IVA | Inventiva |
| 28/03/2024 | 08:00 | GlobeNewswire Inc. | Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur | EU:IVA | Inventiva |
| 27/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva publie ses résultats annuels 2023 | EU:IVA | Inventiva |
| 27/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva reports its 2023 full-year results | EU:IVA | Inventiva |
| 22/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results | EU:IVA | Inventiva |
| 22/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 | EU:IVA | Inventiva |
| 18/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D | EU:IVA | Inventiva |
| 18/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2 | EU:IVA | Inventiva |
| 13/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | EU:IVA | Inventiva |
| 13/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2 | EU:IVA | Inventiva |
| 07/03/2024 | 22:00 | GlobeNewswire Inc. | Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed | EU:IVA | Inventiva |
| 07/03/2024 | 22:00 | GlobeNewswire Inc. | Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH | EU:IVA | Inventiva |
| 15/02/2024 | 22:35 | GlobeNewswire Inc. | Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 | EU:IVA | Inventiva |
| 15/02/2024 | 22:35 | GlobeNewswire Inc. | Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3 | EU:IVA | Inventiva |
| 24/01/2024 | 22:15 | GlobeNewswire Inc. | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | EU:IVA | Inventiva |
| 24/01/2024 | 22:15 | GlobeNewswire Inc. | Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux | EU:IVA | Inventiva |
| 10/01/2024 | 22:00 | GlobeNewswire Inc. | Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank | EU:IVA | Inventiva |
| 10/01/2024 | 22:00 | GlobeNewswire Inc. | Inventiva annonce le tirage de la seconde tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement | EU:IVA | Inventiva |
| 20/12/2023 | 22:00 | GlobeNewswire Inc. | Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program | EU:IVA | Inventiva |
| 20/12/2023 | 22:00 | GlobeNewswire Inc. | Inventiva annonce la randomisation du premier patient en Chine dans l’étude clinique NATiV3 et fait le point sur son programme de développement clinique | EU:IVA | Inventiva |
| 04/12/2023 | 22:05 | GlobeNewswire Inc. | Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH | EU:IVA | Inventiva |
| 04/12/2023 | 22:05 | GlobeNewswire Inc. | Inventiva annonce la recommandation positive du troisième DMC de l’étude clinique de Phase III avec lanifibranor dans la NASH | EU:IVA | Inventiva |
| 21/11/2023 | 22:00 | GlobeNewswire Inc. | Inventiva reports 2023 Third Quarter Financial Information¹ | EU:IVA | Inventiva |
| 21/11/2023 | 22:00 | GlobeNewswire Inc. | Inventiva publie ses informations financières du 3ème trimestre 2023¹ | EU:IVA | Inventiva |
| 06/11/2023 | 22:00 | GlobeNewswire Inc. | Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023 | EU:IVA | Inventiva |
| 06/11/2023 | 22:00 | GlobeNewswire Inc. | Inventiva annonce un abstract « late breaker » et deux abstracts supplémentaires sur son médicament candidat principal, lanifibranor, lors du Liver Meeting™ 2023 organisé par l’AASLD | EU:IVA | Inventiva |